Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- B-cell Non Hodgkin Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: Patients receive anakinra subcutaneously (SC) daily on days 0-13 and axicabtagene ciloleucel via infusion on day 0. After completion of axicabtagene ciloleucel infusion, patients are followed up periodically for up to 90 days.
OUTLINE: Patients receive anakinra subcutaneously (SC) daily on days 0-13 and axicabtagene ciloleucel via infusion on day 0. After completion of axicabtagene ciloleucel infusion, patients are followed up periodically for up to 90 days.
Tracking Information
- NCT #
- NCT04359784
- Collaborators
- National Cancer Institute (NCI)
- Swedish Orphan Biovitrum
- Investigators
- Principal Investigator: Jordan Gauthier Fred Hutch/University of Washington Cancer Consortium